What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We speak with our colleagues Jason Mast an ... Show More
Jul 16
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. ... Show More
35m 32s
Dec 2023
Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs
Laura Chico, Biotechnology Research Analyst at Wedbush Securities and Bloomberg News US Deals Team Leader Matthew Monks share their thoughts on the Bristol Myers acquisition Karuna Therapeutics. John Mowrey, CIO at NFJ Investment Group, explains where to find value in the markets ... Show More
1h 2m